The BioCentury Show

BioCentury Podcasts
  • 5,0 (9)
  • БИОНАУКИ
  • КАЖДЫЕ ДВЕ НЕДЕЛИ
The BioCentury Show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

  1. Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin

    14 НОЯБ.

    Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin

    With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a net trend to the positive, says Sidley Austin’s Robert Darwin, who specializes in global M&A and private equity for life sciences and healthcare companies and investors. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Darwin, who is based in London, discussed the consequences for biotech of the changing forces as we ...

    36 мин.
  2. Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

    31 ОКТ.

    Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

    Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular decisions at the start of his tenure and a surge in cancer drug development over the last 20 years. He believes this and other lessons from the regulation of oncology can be applied broadly across FDA. The BioCentury Show discussed these lessons, as well as Pazdur’s views about advisory committees, pragmatic trials, dose optimization and ...

    42 мин.
  3. Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

    18 ОКТ.

    Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

    With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-prec...

    34 мин.
  4. Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

    4 ОКТ.

    Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

    CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a unique case that is unlikely to set a precedent, former CMS CMO Lee Fleisher told BioCentury. “I do not think this will be repeated,” he said. In an interview with The BioCentury Show's Steve Usdin, Fleisher gives a behind-the-scenes account of the decision-making process, including the role of accelerated approval. He also discusses the opportunitie...

    35 мин.
  5. Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process

    19 СЕНТ.

    Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process

    Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the downmarket. His strategy, to own clinical trials and manufacturing early on, looks particularly prescient in light of the cost and supply constraints threatening many biotechs today. On this episode of The BioCentury Show, Editor in Chief Simone Fishburn sits down with Oyler to discuss the early strategies that are now paying off for the global...

    35 мин.
  6. Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market

    5 СЕНТ.

    Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market

    There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last year in savings attributed to biosimilars. The report also explores the economic, policy and regulatory headwinds that are preventing the industry from generating savings at a level that would have a dramatic effect on the U.S. healthcare system.In an interview with Washington Editor Steve Usdin on The BioCentury Show, Craig Burton, executive direct...

    29 мин.
  7. Popular Episode - Bob Nelsen on AI, China and the IRA

    22 АВГ.

    Popular Episode - Bob Nelsen on AI, China and the IRA

    This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited by the potential for AI to “create a language of biology,” is cautious about investing in China given increasing geopolitical tensions, and is conv...

    36 мин.
  8. Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine

    8 АВГ.

    Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine

    As Jane Grogan anticipates the unmet needs in patients five years from now, she’s harnessing a wave of interest in targeting B cells as a key driver of an immunology expansion at Biogen. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Grogan, who became EVP and head of research of Biogen in October, discusses how she’s approaching the mission to build diversity and balance the risk in the company’s portfolio, extending further into disease areas beyond neurology.V...

    32 мин.
См. все (22)

Оценки и отзывы

5
из 5
Оценок: 9

Об этом подкасте

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

Информация

  • Канал
    BioCentury Podcasts
  • Автор
    BioCentury
  • Годы выхода
    2 тыс.
  • Выпуски
    22
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2024 BioCentury Inc. All Rights Reserved.
  • Сайт подкаста
    The BioCentury Show

Еще от провайдера «BioCentury Podcasts»

Вам может также понравиться

Чтобы прослушивать выпуски с ненормативным контентом, войдите в систему.

Следите за новостями подкаста

Войдите в систему или зарегистрируйтесь, чтобы следить за подкастами, сохранять выпуски и получать последние обновления.
Выберите страну или регион

Африка, Ближний Восток и Индия

Азиатско-Тихоокеанский регион

Европа

Латинская Америка и страны Карибского бассейна

США и Канада